|
CDSCO Sets Ambitious Expansion Plan In
Capacity Building During 2013-20
According to the roadmap prepared by the CDSCO for the period
of 2013 - 20, strengthening of manpower is a key element “by strengthening of
CDSCO manpower by creating additional 1195 new posts, including 64 experts and
additional 4300 personnel for new laboratories, mobile drug testing labs,
E-governance, training academy,” it said.
According to the roadmap and vision published by the CDSCO,
e-governance will be another important area to increase transparency and
credibility. “All offices of zonal / sub-zonal / port offices / laboratories of
CDSCO and offices of State Drugs Controllers will be interlinked for fast
communication, IT enabled services, preparation of National Registry, Video
Conferencing, archiving of all files etc,” it said.
“Consumer awareness programmes to educate and sensitise
consumers, medical care providers etc. on drug safety alerts, promotion of
generic drugs, self medication issues, etc.; setup of eight new Central Drugs
Testing Laboratories with a capacity to test around 8000 samples per annum by
each laboratory; Upgradation of existing six Central Drugs Laboratories;
Upgradation of existing CDSCO zonal/subzonal and port offices; set up five new
Central Cosmetics Testing Labs, three new Central Diagnostic kit labs and five
new Central Medical Devices Testing Laboratories; set up of 20 mini drug testing
labs at port offices of CDSCO to monitor quality of imported and exported drugs;
purchase of 20 mobile drug testing vans; set up of five new Central Cosmetics
Testing Labs, three new Central Diagnostic Kit Labs and five new Central Medical
Devices Testing Laboratories,” the vision document says.
( Ref:
http://pharmabiz.com/NewsDetails.aspx?aid=70407&sid=1 )
Taking A PEEK At New Implants
Solvay Specialty Polymers expands range of PEEK resins for
implantable Medical Devices.
A new radio-visible compound grade, Zeniva ZA-520, provides
image contrasting capabilities for visualisation with x-ray CT and MRI imaging
systems.
Zeniva ZA-520 compound provides visibility of an implant
without the artifacts common with competitive metal-based materials, according
to Solvay.
The new compound is available in resin form - for injection
moulding - and rod stock which can be high-precision machined.
On the basis of biocompatibility testing to ISO 10993
standards, Zeniva PEEK is claimed to demonstrate no evidence of cytotoxicity,
sensitisation, irritation or acute systemic toxicity.
( Ref:
http://www.prw.com/subscriber/headlines2.html?cat=1&id=1309 )
|
